Daniel O’Day is getting about $30 million in cash and stock to save the stagnant Gilead Sciences (GILD). On Thursday, investors get their first chance to decide whether he’s worth the money.
O’Day, who started as Gilead CEO in March, will host his first quarterly earnings call after the market closes, giving the Roche (RHHBY) veteran a chance to explain his vision for the company, weigh in on some recent setbacks, and get some practice answering the question he’ll face every three months from now on: What are you going to buy?
About the Author Reprints
